No Prescription |
 |
 | ||
|
Amantadine Generic Symadine |
|
| ||
No Prescription » Prescription Drugs 1 » Amantadine Generic Symadine USFDA Approved Medicine for the treatment of Influenzavirus A[2][3][4][5] in adults and to help reduce symptoms of Parkinson's disease and drug-induced extrapyramidal syndromes.Prevention and treatment of signs and symptoms of infection caused by various strains of influenza A virusAmantadine is effective in the treatment of active influenza A infection when administered within 48 hours after the onset of symptoms.Treatment of Parkinson's diseaseIdiopathic parkinsonism Secondary parkinsonism (e.g. of post-encephalitic type of cerebrovascular origin or drug-induced parkinsonism) (see Interaction with other medicinal products and other forms of interaction). Amantadine can be given alone for initial therapy or combined with anticholinergic drugs or L-dopa. Buy Amantadine Generic Symadine and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Amantadine Generic Symadine: Product Type: Prescription Drugs 1 Amantadine ( Generic Symadine Symmetrel ) Amantadine (Generic Symadine Symmetrel) Generic Symadine Symmetrel 100mg 100 Capsules 200(2 x 100) Caps 400(4 x 100) Caps Generic Symadine Symmetrel Amantadine
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
